{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:26:18Z","timestamp":1791728778645,"version":"4.3.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40262-026-01651-3","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T05:05:47Z","timestamp":1779858347000},"page":"1073-1085","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Vutrisiran-Mediated Knockdown of Transthyretin in Patients with ATTR Amyloidosis"],"prefix":"10.1007","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9233-9831","authenticated-orcid":false,"given":"Marianna","family":"Fontana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5971-1235","authenticated-orcid":false,"given":"Vincent","family":"Algalarrondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5470-2257","authenticated-orcid":false,"given":"Pablo","family":"Garcia-Pavia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5400-5008","authenticated-orcid":false,"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6174-9232","authenticated-orcid":false,"given":"Julian D.","family":"Gillmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1622-0732","authenticated-orcid":false,"given":"Francesco","family":"Cappelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiranmai","family":"Kolachana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuqing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyawan","family":"Jadhav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Mehrotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Robbie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1248-616X","authenticated-orcid":false,"given":"Prajakta","family":"Badri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"1651_CR1","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","volume":"15","author":"D Adams","year":"2019","unstructured":"Adams D, Koike H, Slama M, Coelho T. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol. 2019;15:387\u2013404. https:\/\/doi.org\/10.1038\/s41582-019-0210-4.","journal-title":"Nat Rev Neurol"},{"key":"1651_CR2","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73:2872\u201391. https:\/\/doi.org\/10.1016\/j.jacc.2019.04.003.","journal-title":"J Am Coll Cardiol"},{"key":"1651_CR3","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/s13023-023-02962-5","volume":"18","author":"L Gentile","year":"2023","unstructured":"Gentile L, Coelho T, Dispenzieri A, Concei\u00e7\u00e3o I, Waddington-Cruz M, Kristen A, et al. A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS). Orphanet J Rare Dis. 2023;18:350. https:\/\/doi.org\/10.1186\/s13023-023-02962-5.","journal-title":"Orphanet J Rare Dis"},{"key":"1651_CR4","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/s0950-3579(05)80120-7","volume":"8","author":"PN Hawkins","year":"1994","unstructured":"Hawkins PN. Diagnosis and monitoring of amyloidosis. Baillieres Clin Rheumatol. 1994;8:635\u201359. https:\/\/doi.org\/10.1016\/s0950-3579(05)80120-7.","journal-title":"Baillieres Clin Rheumatol"},{"key":"1651_CR5","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00041552-200211000-00013","volume":"11","author":"PN Hawkins","year":"2002","unstructured":"Hawkins PN. Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. Curr Opin Nephrol Hypertens. 2002;11:649\u201355. https:\/\/doi.org\/10.1097\/00041552-200211000-00013.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"1651_CR6","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1046\/j.1365-2141.2003.04433.x","volume":"122","author":"HJ Lachmann","year":"2003","unstructured":"Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Pepys MB, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol. 2003;122:78\u201384. https:\/\/doi.org\/10.1046\/j.1365-2141.2003.04433.x.","journal-title":"Br J Haematol"},{"key":"1651_CR7","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1056\/NEJMoa070265","volume":"356","author":"HJ Lachmann","year":"2007","unstructured":"Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356:2361\u201371. https:\/\/doi.org\/10.1056\/NEJMoa070265.","journal-title":"N Engl J Med"},{"key":"1651_CR8","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","volume":"30","author":"G Palladini","year":"2012","unstructured":"Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30:4541\u20139. https:\/\/doi.org\/10.1200\/JCO.2011.37.7614.","journal-title":"J Clin Oncol"},{"key":"1651_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/S0140-6736(00)05252-1","volume":"358","author":"JD Gillmore","year":"2001","unstructured":"Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001;358:24\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(00)05252-1.","journal-title":"Lancet"},{"key":"1651_CR10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","volume":"14","author":"M Fontana","year":"2021","unstructured":"Fontana M, Martinez-Naharro A, Chacko L, Rowczenio D, Gilbertson JA, Whelan CJ, et al. Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression. JACC Cardiovasc Imaging. 2021;14:189\u201399. https:\/\/doi.org\/10.1016\/j.jcmg.2020.07.043.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"3","key":"1651_CR11","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/mus.28026","volume":"69","author":"C Karam","year":"2024","unstructured":"Karam C, Mauermann ML, Gonzalez-Duarte A, Kaku MC, Ajroud-Driss S, Brannagan TH 3rd, et al. Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: recommendations from a panel of experts. Muscle Nerve. 2024;69(3):273\u201387. https:\/\/doi.org\/10.1002\/mus.28026.","journal-title":"Muscle Nerve"},{"key":"1651_CR12","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/eurheartj\/ehae811","volume":"46","author":"E Gonzalez-Lopez","year":"2025","unstructured":"Gonzalez-Lopez E, Maurer MS, Garcia-Pavia P. Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine. Eur Heart J. 2025;46:999\u20131013. https:\/\/doi.org\/10.1093\/eurheartj\/ehae811.","journal-title":"Eur Heart J"},{"key":"1651_CR13","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/cpt.1974","volume":"109","author":"BA Habtemariam","year":"2021","unstructured":"Habtemariam BA, Karsten V, Attarwala H, Goel V, Melch M, Clausen VA, et al. Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting N-acetylgalactosamine-small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects. Clin Pharmacol Ther. 2021;109:372\u201382. https:\/\/doi.org\/10.1002\/cpt.1974.","journal-title":"Clin Pharmacol Ther"},{"key":"1651_CR14","unstructured":"Alnylam Pharmaceuticals Inc. US prescribing information: AMVUTTRA (vutrisiran) injection, for subcutaneous use. Food and Drug Administration 2022. https:\/\/www.alnylam.com\/sites\/default\/files\/pdfs\/amvuttra-us-prescribing-information.pdf. Accessed July 2025."},{"key":"1651_CR15","unstructured":"European Medicines Agency. Summary of product characteristics: AMVUTTRA (vutrisiran) 25 mg solution for injection. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/amvuttra-epar-product-information_en.pdf. Accessed July 2025."},{"key":"1651_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","volume":"30","author":"D Adams","year":"2023","unstructured":"Adams D, Tournev IL, Taylor MS, Coelho T, Plant\u00e9-Bordeneuve V, Berk JL, et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2023;30:1\u20139. https:\/\/doi.org\/10.1080\/13506129.2022.2091985.","journal-title":"Amyloid"},{"key":"1651_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2409134","volume":"392","author":"M Fontana","year":"2025","unstructured":"Fontana M, Berk JL, Gillmore JD, Witteles RM, Grogan M, Drachman B, et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N Engl J Med. 2025;392:33\u201344. https:\/\/doi.org\/10.1056\/NEJMoa2409134.","journal-title":"N Engl J Med"},{"key":"1651_CR18","unstructured":"Jadhav SB, Lee J, Melch M, Badri P, Vest J, Mehrotra N, et al. Population pharmacokinetic\/pharmacodynamic (PK\/PD) analysis of vutrisiran in healthy subjects and hATTR amyloidosis patients with polyneuropathy. 2022. American conference on pharmacometrics (ACoP13), Denver, Colorado, October 30\u2013November 2, 2022."},{"key":"1651_CR19","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"JD Gillmore","year":"2018","unstructured":"Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39:2799\u2013806. https:\/\/doi.org\/10.1093\/eurheartj\/ehx589.","journal-title":"Eur Heart J"},{"key":"1651_CR20","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41467-018-02989-4","volume":"9","author":"MM Janas","year":"2018","unstructured":"Janas MM, Schlegel MK, Harbison CE, Yilmaz VO, Jiang Y, Parmar R, et al. Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity. Nat Commun. 2018;9:723. https:\/\/doi.org\/10.1038\/s41467-018-02989-4.","journal-title":"Nat Commun"},{"key":"1651_CR21","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.drudis.2008.05.007","volume":"13","author":"JK Watts","year":"2008","unstructured":"Watts JK, Deleavey GF, Damha MJ. Chemically modified siRNA: tools and applications. Drug Discov Today. 2008;13:842\u201355. https:\/\/doi.org\/10.1016\/j.drudis.2008.05.007.","journal-title":"Drug Discov Today"},{"key":"1651_CR22","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40120-024-00595-9","volume":"13","author":"M Luigetti","year":"2024","unstructured":"Luigetti M, Quan D, Berk JL, Concei\u00e7\u00e3o I, Misumi Y, Chao CC, et al. Impact of baseline neuropathy severity on vutrisiran treatment response in the phase 3 HELIOS-A study. Neurol Ther. 2024;13:625\u201339. https:\/\/doi.org\/10.1007\/s40120-024-00595-9.","journal-title":"Neurol Ther"},{"key":"1651_CR23","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1007\/s40120-023-00522-4","volume":"12","author":"L Obici","year":"2023","unstructured":"Obici L, Ajroud-Driss S, Lin KP, Berk JL, Gillmore JD, Kale P, et al. Impact of vutrisiran on quality of life and physical function in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. Neurol Ther. 2023;12:1759\u201375. https:\/\/doi.org\/10.1007\/s40120-023-00522-4.","journal-title":"Neurol Ther"},{"key":"1651_CR24","doi-asserted-by":"crossref","unstructured":"Maurer MS, Berk J, Damy T, Sheikh FH, Gonz\u00e1lez-Costello J, Morbach C, et al. Exploratory analyses from HELIOS-B, a phase 3 study of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. 2024. HFSA annual scientific meeting, Atlanta, Georgia, September 27\u201330, 2024.","DOI":"10.1016\/j.acvd.2024.10.013"},{"key":"1651_CR25","doi-asserted-by":"publisher","first-page":"e004000","DOI":"10.1161\/CIRCHEARTFAULRE.117.004000","volume":"11","author":"JLS Hanson","year":"2018","unstructured":"Hanson JLS, Arvanitis M, Koch CM, Berk JL, Ruberg FL, Prokaeva T, et al. Use of serum transthyretin as a prognostic indicator and predictor of outcome in cardiac amyloid disease associated with wild-type transthyretin. Circ Heart Fail. 2018;11:e004000. https:\/\/doi.org\/10.1161\/CIRCHEARTFAULRE.117.004000.","journal-title":"Circ Heart Fail"},{"key":"1651_CR26","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/13506120802525285","volume":"15","author":"J Buxbaum","year":"2008","unstructured":"Buxbaum J, Koziol J, Connors LH. Serum transthyretin levels in senile systemic amyloidosis: Effects of age, gender and ethnicity. Amyloid. 2008;15:255\u201361. https:\/\/doi.org\/10.1080\/13506120802525285.","journal-title":"Amyloid"},{"key":"1651_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1716153.","journal-title":"N Engl J Med"},{"key":"1651_CR28","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","volume":"389","author":"MS Maurer","year":"2023","unstructured":"Maurer MS, Kale P, Fontana M, Berk JL, Grogan M, Gustafsson F, et al. Patisiran treatment in patients with transthyretin cardiac amyloidosis. N Engl J Med. 2023;389:1553\u201365. https:\/\/doi.org\/10.1056\/NEJMoa2300757.","journal-title":"N Engl J Med"},{"key":"1651_CR29","unstructured":"Alnylam Pharmaceuticals Inc., Anylam Netherlands B.V. Periodic benefit-risk evaluation report (PBRER) 07 for AMVUTTRA\u00ae (vutrisiran). Unpublished report submitted to the US Food and Drug Administration (FDA) and other health authorities; February 5, 2026."},{"key":"1651_CR30","unstructured":"Alnylam Pharmaceuticals Inc., Alnylam Netherlands B.V. Periodic benefit-risk evaluation report (PBRER) 10 for ONPATTRO\u00ae (patisiran). Unpublished report submitted to the US Food and Drug Administration (FDA) and other health authorities; October 2, 2025."},{"key":"1651_CR31","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1001\/jamaneurol.2024.4631","volume":"82","author":"D Adams","year":"2025","unstructured":"Adams D, Wixner J, Polydefkis M, Berk JL, Concei\u00e7\u00e3o IM, Dispenzieri A, et al. Five-year results with patisiran for hereditary transthyretin amyloidosis with polyneuropathy: a randomized clinical trial with open-label extension. JAMA Neurol. 2025;82:228\u201336. https:\/\/doi.org\/10.1001\/jamaneurol.2024.4631.","journal-title":"JAMA Neurol"},{"key":"1651_CR32","unstructured":"Cauquil C, Adams D, Polydefkis M, Gonzalez-Duarte A, Waddington-Cruz M, Sekijima Y, et al. HELIOS-A: 18-month randomised treatment extension analysis of vutrisiran in patients with hereditary transthyretin amyloidosis with polyneuropathy. Poster presented at: Soci\u00e9t\u00e9 Francophone du Nerf P\u00e9riph\u00e9rique (SFNP) 2025; 2025 Jan 31\u2013Feb 1; Paris, France. https:\/\/www.rnaiscience.com\/sites\/default\/files\/2025-01\/HELIOS-A_18-month-RTE_English.pdf. Accessed 15 May 2026."},{"issue":"Suppl 1","key":"1651_CR33","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf784.1222","volume":"46","author":"P Garcia-Pavia","year":"2025","unstructured":"Garcia-Pavia P, Witteles R, Morbach C, Delgado D, Kitaoka H, Maurer MS, et al. HELIOS-B: 12-month results from the open-label extension period of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. Eur Heart J. 2025;46(Suppl 1):ehaf784.1222. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf784.1222.","journal-title":"Eur Heart J"},{"key":"1651_CR34","doi-asserted-by":"publisher","first-page":"102066","DOI":"10.1016\/j.jacadv.2025.102066","volume":"4","author":"RM Witteles","year":"2025","unstructured":"Witteles RM, Garcia-Pavia P, Morbach C, Gillmore JD, Taylor MS, Concei\u00e7\u00e3o I, et al. Vutrisiran in transthyretin amyloidosis: a pooled safety analysis of HELIOS-A and HELIOS-B. JACC Adv. 2025;4:102066. https:\/\/doi.org\/10.1016\/j.jacadv.2025.102066.","journal-title":"JACC Adv"},{"key":"1651_CR35","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/jcph.1480","volume":"60","author":"X Zhang","year":"2020","unstructured":"Zhang X, Goel V, Attarwala H, Sweetser MT, Clausen VA, Robbie GJ. Patisiran pharmacokinetics, pharmacodynamics, and exposure-response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin-mediated (hATTR) amyloidosis. J Clin Pharmacol. 2020;60:37\u201349. https:\/\/doi.org\/10.1002\/jcph.1480.","journal-title":"J Clin Pharmacol"},{"key":"1651_CR36","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s10741-024-10444-4","volume":"30","author":"AA Girard","year":"2025","unstructured":"Girard AA, Sperry BW. Contextualizing the results of HELIOS-B in the broader landscape of clinical trials for the treatment of transthyretin cardiac amyloidosis. Heart Fail Rev. 2025;30:69\u201373. https:\/\/doi.org\/10.1007\/s10741-024-10444-4.","journal-title":"Heart Fail Rev"},{"key":"1651_CR37","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","volume":"146","author":"A Ioannou","year":"2022","unstructured":"Ioannou A, Patel RK, Razvi Y, Porcari A, Sinagra G, Venneri L, et al. Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years. Circulation. 2022;146:1657\u201370. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.060852.","journal-title":"Circulation"},{"key":"1651_CR38","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1007\/s12325-024-02891-0","volume":"41","author":"MS Maurer","year":"2024","unstructured":"Maurer MS, Soman P, Hernandez A, Garcia-Pavia P, Signorovitch J, Wei LJ, et al. Advancing transthyretin amyloidosis drug development in an evolving treatment landscape: Amyloidosis Forum meeting proceedings. Adv Ther. 2024;41:2723\u201342. https:\/\/doi.org\/10.1007\/s12325-024-02891-0.","journal-title":"Adv Ther"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01651-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01651-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01651-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T05:36:55Z","timestamp":1783748215000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01651-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1651"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01651-3","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Alnylam Pharmaceuticals Inc. The funder collaborated with the authors during the study design, data collection, data analysis, data interpretation, and writing of the report. All authors had full access to all the data in the study and took final responsibility for the decision to submit the manuscript for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"M.F. reports research support from AstraZeneca; consultancy and\/or advisory board membership for Alexion, Alnylam Pharmaceuticals, Attralus, Caelum Biosciences, Intellia Therapeutics, Ionis Pharmaceuticals, Janssen Pharmaceuticals, Lexeo Therapeutics, Novo Nordisk, Pfizer, and Prothena; support for attending meetings from Alnylam Pharmaceuticals, AstraZeneca, and Attralus; and ownership of equity in Lexeo Therapeutics and Mycardium. V.A. reports consulting fees and research funding from Alnylam Pharmaceuticals, AstraZeneca, Bayer, Biotronik, and Pfizer. P.G.-P. reports speaking fees from Alnylam Pharmaceuticals, AstraZeneca, BridgeBio, Intellia Therapeutics, Ionis Pharmaceuticals, Novo Nordisk, and Pfizer; consulting fees from Alexion, Alnylam Pharmaceuticals, AstraZeneca, Attralus, Bayer, BridgeBio, Intellia Therapeutics, Ionis Pharmaceuticals, Neuroimmune, Novo Nordisk, and Pfizer; and research\/educational support to their institution from Alnylam Pharmaceuticals, AstraZeneca, BridgeBio, Intellia Therapeutics, Novo Nordisk, and Pfizer. M.S.M. reports receiving research support from Alnylam Pharmaceuticals, Attralus, BridgeBio, Intellia Therapeutics, and Ionis Pharmaceuticals; and consulting fees from Akcea Therapeutics, Alnylam Pharmaceuticals, AstraZeneca, Intellia Therapeutics, Novo Nordisk, and Roche. J.D.G. reports research support from Alnylam Pharmaceuticals; consulting fees from Alnylam Pharmaceuticals, AstraZeneca, BridgeBio, Intellia Therapeutics, Ionis Pharmaceuticals, and Lycia Therapeutics; and payment for lectures or speaker fees from Alnylam Pharmaceuticals and AstraZeneca. F.C. reports consulting fees from Alnylam Pharmaceuticals, AstraZeneca, Bayer, BridgeBio, and Pfizer. K.K., X.G., S.J., G.R., and P.B. are employees of and own shares in Alnylam Pharmaceuticals. N.M. was a previous employee of Alnylam Pharmaceuticals and own shares in Alnylam Pharmaceuticals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The studies were conducted in accordance with all applicable regulatory requirements, the International Council for Harmonisation Good Clinical Practice guidelines, and the principles of the Declaration of Helsinki. The institutional review board or independent ethics committee at each center approved the study protocol and amendments.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Access to anonymized individual participant data that support these results is made available 12 months after trial completion and not less than 12 months after the product and indication have been approved in the USA and\/or the EU. Data will be provided contingent upon the approval of a research proposal and the execution of a data sharing agreement. Requests for access to data can be submitted via the website:\n                      \n                      .","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"MF, VA, PG-P, MSM, JDG and FC were responsible for the acquisition of the data. XG was responsible for data analysis. All authors contributed to the interpretation of the data and the development and final approval of the manuscript. All authors take accountability for the work.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Consent was obtained from participants in all trials.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Written informed consent was obtained for all participants before conducting any study procedures.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}}]}}